

HT F Homogeneous PARP Inhibition Assay Kit

96 Tests

Cat# 4690-096-K

**HT Fluorescent Screening Assay
for PARP Inhibitors**

HT F Homogeneous PARP Inhibition Assay Kit

Cat# 4690-096-K

Table of Contents

	Page
I. Introduction	1
II. Precautions and Limitations	2
III. Materials Supplied	2
IV. Materials/Equipment Required but not Supplied	2
V. Reagent Preparation	2
VI. Assay Design	4
VII. Data Interpretation	6
VIII. References	9
IX. Troubleshooting	9
X. Related Products Available From Trevigen	10


I. Introduction

Poly (ADP-ribose) polymerase 1 (PARP-1) plays an active role in various DNA repair processes by binding to DNA single-strand breaks and catalyzing the formation of polymers of ADP-ribose (PAR) onto itself and other proteins, resulting in NAD⁺ depletion.[1-3] PARP inhibitors are potential chemotherapeutic agents for cancer treatment since they sensitize cells to DNA damaging agents, and recently, these inhibitors have been shown to have a high potential therapeutic index for cells homozygous mutant for the BRCA1 and BRCA2 genotypes.[4-6]

Trevigen's **Homogeneous PARP Inhibition Assay** is a highly sensitive fluorescent screening assay for the rapid identification of PARP-1 inhibitors in an *in vitro* system. This one hour endpoint assay is performed in two successive steps requiring only the consecutive addition of reaction components. A PARP reaction is first performed followed by a detection step (Figure 1). Inhibitors are identified by an increase in fluorescent signal when PARP mediated NAD⁺ depletion is inhibited. The level of NAD⁺ is coupled to a cycling assay involving alcohol dehydrogenase and diaphorase. Each time NAD⁺ cycles through these coupled reactions, a molecule of highly fluorescent resorufin is generated. Alcohol dehydrogenase (AD) reduces NAD⁺ to NADH, while the diaphorase cycles NADH back to NAD⁺ with the generation of a highly fluorescent resorufin molecule (from the non-fluorescent substrate, resazurin). The number of cycles can be controlled by the time of incubation to adjust assay sensitivity, as needed, and the reaction is terminated by the addition of a stop solution. In addition, the assay can be used to determine relative IC₅₀ values for PARP inhibitors and is capable of detecting as little as 10% inhibition of PARP-1 activity.

The Homogeneous PARP Inhibition Assay is designed for the screening of PARP inhibitors using a NAD concentration below the Km of PARP. Once potential inhibitors are identified, accurate Ki values using Michaelis-Menton kinetics can be determined using Trevigen's HT Universal PARP Assay kits (cat# 4676-096-K or 4677-096-K).

Figure 1: PARP Inhibition Assay



II. Precautions and Limitations

1. For Research Use Only. Not for use in diagnostic procedures.
2. The physical, chemical, and toxicological properties of the chemicals and reagents contained in the Homogeneous PARP Inhibition Assay may not yet have been fully investigated. Therefore, Trevigen recommends the use of gloves, lab coats, and eye protection while using any of these chemical reagents. Trevigen assumes no liability for damage resulting from handling or contact with these products. MSDS are available on request.
3. 10X Resazurin is light sensitive and 10X Cycling Enzymes are sensitive to oxidation.
4. Cycling reaction is sensitive to reducing agents. Do not add DTT to reactions.

III. Materials Supplied

Catalog #	Component	Quantity	Storage
4690-096-01	10X Cycling Enzymes (50% glycerol)	600 µl	-20 °C
4690-096-02	200 nM NAD (in 3 vials)	3.5 ml	-20 °C
4690-096-03	PARP HSA Enzyme, 200 ng/µl	100 µl	-20 °C
4690-096-04	Activated DNA, 200 ng/µl	600 µl	-20 °C
4690-096-05	10X Resazurin	600 µl	RT
4690-096-06	10X Buffer (1M Tris-HCl, pH 8)	3.5 ml	RT
4690-096-07	Stop Solution	6 ml	RT

IV. Materials/Equipment Required But Not Supplied

1. PARP inhibitors to be tested.
2. Sterile distilled water (dH₂O)
3. 96 well round bottom plate suitable for 150 µl volume fluorescent assay (non-treated Nunc U96 MicroWell™ Plates).
4. 2 µl, 2 - 200 µl and 100-1000 µl pipettes and pipette tips
5. Multichannel pipettor for 25 µl and 50 µl volumes
6. 1.5 ml microtubes
7. 96-well fluorescent plate reader (544 nm excitation/ 590 nm emission filters) with gain adjustment
8. 95% ethanol (Reagent grade or higher)

V. Reagent Preparation

The preparation of reagents is based upon performance of a standard curve and the testing of inhibitors as discussed in Section VI. Assay Design.

1. 2X NAD Standards

2X NAD Standards are prepared using 200 nM NAD and 1X Buffer as described in Table 1. Standards may be stored at -20°C for later use. Prepare 1X Buffer by adding 110 µl 10X Buffer to 990 µl dH₂O.

Table 1: Preparation of 2X NAD Standards

2X NAD Standard	Vol of 200 nM stock	Vol of 1X Buffer
200 nM	3.5 ml provided	X
160 nM	200 µl	50 µl
120 nM	150 µl	100 µl
80 nM	100 µl	150 µl
40 nM	50 µl	200 µl
20 nM	25 µl	225 µl
0 nM	X	250 µl

2. Inhibitor Dilutions

It is preferred to dilute PARP inhibitors in 1X Buffer to 50X concentration. PARP inhibitors are added in a 1 microliter volume and duplicate reactions are recommended.

Dilution ranges for PARP inhibitors will vary. For example, Phenanthridinone has a published K_i of 305 nM; therefore, ~ 50% inhibition of PARP activity is expected.

If PARP inhibitors are diluted in DMSO, then DMSO should also be added to wells containing NAD standards as described in Section VI. Assay Design. DMSO concentrations of 1% will show slight inhibition of cycling assay.

Note: ~1.5 ml 10X Buffer is needed for preparation of NAD Standards, PARP Mix and Cycling Mix.

3. PARP Plus/Minus Mix (prepare directly before use).

PARP Minus Mix is dispensed using single channel pipette and PARP Plus Mix using multi channel pipette from Reagent Plate (Section VI. Assay Design and Table 3).

Make PARP Mix as follows (sufficient to aliquot 48 wells):

	Minus	x15	Plus	x44
10X Buffer	5 μ l	75 μ l	5 μ l	220 μ l
Activated DNA	5 μ l	75 μ l	5 μ l	220 μ l
dH ₂ O	15 μ l	225 μ l	14 μ l	616 μ l
PARP HSA Enzyme			<u>1 μl</u>	<u>44 μl</u>
Total volume of PARP Mix:	25 μ l	375 μ l	25 μ l	1100 μ l

4. Cycling Mix (prepare directly before use).

The Cycling Mix is light sensitive and should be prepared just prior to use, and equilibrated to room temperature. Sufficient reagents are provided if Cycling Mix is dispensed using a multichannel pipette from a Reagent Plate (Section VI. Assay Design and Table 3).

Order of addition: When preparing Cycling Mix, combine and mix dH₂O, 10X Buffer and 95% EtOH first, **before** adding 10X Resazurin and 10X Cycling Enzymes, respectively.

Make Cycling Mix as follows (sufficient to aliquot 48 wells):

	<u>1 well</u>	<u>x60</u>
dH ₂ O	33.9 μ l	2034 μ l
10X Buffer	5.0 μ l	300 μ l
Reagent EtOH (95%)	1.1 μ l	66 μ l
10X Resazurin	5.0 μ l	300 μ l
10X Cycling Enzymes	<u>5.0 μl</u>	<u>300 μl</u>
Total volume:	50.0 μ l	3.0 ml

5. Stop Solution

Stop Solution is ready for use. Sufficient reagent is provided if Stop Solution is dispensed using a multichannel pipette from a Reagent Plate (Section VI. Assay Design and Table 3). Do not refrigerate or freeze stop solution.

VI. Assay Design for PARP Inhibitor Testing

It is recommended that all reactions be performed in duplicate and a standard curve generated with each experiment. Reactions are assembled in a 96 well fluorescent plate to accommodate a final assay volume of 150 μ l/well, and detection using a fluorescent plate reader. A 30 minute PARP reaction is performed followed by a cycling reaction to generate a fluorescent signal indicative of the level of PARP inhibition. The cycling reaction can be monitored in real-time to assure linearity of standard curve or at endpoint through the addition of a Stop Solution.

Use of separate assay and reagent plates is recommended. A suggested assay plate setup for the testing of 16 inhibitor concentrations (columns 3 to 6) is shown in Table 2. Table 3 lists suggested volumes for a Reagent Plate for addition of reaction components to the assay plate using a multichannel pipette. In the initial screen of potential PARP inhibitors (Table 2), a background control (1A and 2A), standards (1B to 1G and 2B to 2G), and PARP control (1H and 2H) are recommended. Once inhibitors are identified, titrations can be performed to determine the relative IC₅₀ values. When determining IC₅₀ values, an additional inhibitor control is recommended to assure no inhibition of the cycling reaction. Table 4 lists the five types of reactions and the components present during the reaction.

Table 2: Assay Plate Setup (48 wells)

	1 (Standards)	2 (Standards)	3 (Inhibitors)	4 (Inhibitors)	5 (Inhibitors)	6 (Inhibitors)
A	0 nM NAD	0 nM NAD	I1	I1	I9	I9
B	10 nM NAD	10 nM NAD	I2	I2	I10	I10
C	20 nM NAD	20 nM NAD	I3	I3	I11	I11
D	40 nM NAD	40 nM NAD	I4	I4	I12	I12
E	60 nM NAD	60 nM NAD	I5	I5	I13	I13
F	80 nM NAD	80 nM NAD	I6	I6	I14	I14
G	100 nM NAD	100 nM NAD	I7	I7	I15	I15
H	100nM NAD/PARP	100nM NAD/PARP	I8	I8	I16	I16

Table 3: Reagent Plate (48 wells):

	200 nM NAD	PARP Plus Mix	Cycling Mix	Cycling Mix	Stop Solution	Stop Solution
A	125 μ l	125 μ l	175 μ l	175 μ l	175 μ l	175 μ l
B	125 μ l	125 μ l	175 μ l	175 μ l	175 μ l	175 μ l
C	125 μ l	125 μ l	175 μ l	175 μ l	175 μ l	175 μ l
D	125 μ l	125 μ l	175 μ l	175 μ l	175 μ l	175 μ l
E	125 μ l	125 μ l	175 μ l	175 μ l	175 μ l	175 μ l
F	125 μ l	125 μ l	175 μ l	175 μ l	175 μ l	175 μ l
G	125 μ l	125 μ l	175 μ l	175 μ l	175 μ l	175 μ l
H	125 μ l	125 μ l	175 μ l	175 μ l	175 μ l	175 μ l

Table 4: Reaction Type and Components Present

Reaction Type	NAD	PARP enzyme	Inhibitor	Cycling
1. Background control				X
2. Standards	x			X
3. PARP control	x	X		X
4. Inhibitor test	x	X	x	X
5. Inhibitor control	x		x	X

A. PARP Reaction

1. Aliquot 25 μ l of 1X Buffer to wells containing 0 nM NAD (Table 2, 1A and 2A).
2. Aliquot 25 μ l of appropriate 2X NAD Standards (V.1 Reagent Preparation) to wells in 1B to 1G and 2B to 2G (Table 2) for Standard Curve. For example, 25 μ l of 20 nM NAD (2X Standard) is aliquoted into wells 1B and 2B to generate 10 nM NAD Standard.
3. Aliquot 25 μ l of 200 nM NAD (2X Standard) to 1H and 2H (Table 2) for PARP Control.
4. Aliquot 25 μ l of 200 nM NAD (2X Standard) to all wells in columns 3 to 6 (the Inhibitor Wells) (Table 2), using a multichannel pipette, from the reagent plate (Table 3).
5. Aliquot 1 μ l of inhibitor concentrations (V.2 Reagent Preparation) to appropriate wells in columns 3 to 6. If inhibitors were diluted in DMSO, add 1 μ l DMSO to standards (1A to 1H and 2A to 2H).

Note: DMSO is inhibitory to the PARP and cycling reactions. DMSO concentrations greater than 2% in the PARP reaction are not recommended.

6. Aliquot 25 μ l of PARP Mix minus Enzyme (V.3 Reagent Preparation) to 1A to 1G and 2A to 2G. Mix by gently pipetting up and down.
7. Aliquot 25 μ l of PARP Mix plus Enzyme (V.3 Reagent Preparation) to 1H and 2H and to all inhibitor wells in columns 3 to 6, using a multichannel pipette, from the reagent plate (Table 3). Mix gently.
8. Incubate at room temperature for 30 min.

B. Cycling Reaction

1. Aliquot 50 μ l of Cycling Mix (V.4 Reagent Preparation) to all wells using multichannel pipette from the reagent plate (Table 3). Mix gently.
2. Incubate at room temperature for 15-40 minutes. Shield plate from direct light.

3. Aliquot 50 μ l Stop Solution to all wells, using a multichannel pipette, from the reagent plate using the same order as addition of Cycling Mix. Gently mix.
4. The increase in fluorescence (with excitation at 544 nm and emission at 590 nm) is measured using fluorescence plate reader.

Note: Recommend performing gain adjustment for entire plate. The purpose of the gain adjustment is to optimize the signal amplification so that the results have the maximum sensitivity and dynamic range. Maximal readings are expected from wells 1G and 2G and from some inhibitor wells.


VII. Data Interpretation.

A. Screening


1. Calculate the average fluorescent value of all duplicates and subtract the value of "0 nM NAD Standard" to obtain relative fluorescent unit (RFU) values.
2. In EXCEL, use column chart plot to illustrate data (Figure 2).
 - a. In Figure 2A, the NAD standards are on the X axis with their respective RFU values on the Y axis.
 - b. In Figure 2B, the inhibitors present during the PARP reaction are on the X axis with their respective RFU values on Y axis. Control reactions containing 100 nM NAD minus and plus PARP are also plotted. In the absence of PARP activity maximal signal is observed, while minimal signal is observed when PARP activity is present.
 - c. At a given concentration of inhibitor, PARP inhibition can be monitored based on the final NAD concentration in the assay. In Figure 2B, at 100 nM Phenanthridinone and EB47 show significant inhibition of PARP activity (maximal signal).

Figure 2: Endpoint data.

A. NAD Standards



B. Inhibition Assay



B. Calculation of relative IC₅₀ values

The Homogeneous PARP Inhibition Assay is designed for the screening of PARP inhibitors using a NAD concentration below the K_m of PARP. Once potential inhibitors are identified, accurate K_i values using Michaelis-Menton kinetics can be determined using Trevigen's HT Universal PARP Assay kits (cat# 4676-096-K or 4677-096-K).


1. Calculate the average fluorescence value of all duplicates for each concentration of inhibitor and subtract value of "0 nM NAD Standard" to obtain RFU values (Table 5).

Table 5: EB47 Data. Background (14401).

nM EB47	Average Fluorescence	RFU
1	20452	6051
10	30584	16183
100	57454	43053

2. In Excel, use XY (scatter) to plot "nM of NAD Standard" (X Axis) versus RFU (Y axis). Generate a trend line using a two order polynomial and force the Y intercept through zero (Figure 3). Display equation on graph.

Figure 3: NAD Standard Curve



3. Set up the quadratic equation from the Standard Curve in Excel to calculate the amount of NAD remaining (also % inhibition) at each inhibitor concentration using the observed RFU. Worksheet is available on Trevigen web site (Figure 4).

- a. The general quadratic equation is given by $ax^2 + bx + c = 0$.
- b. Rearrange the equation generated from the Standard Curve.

$$-4.4601x^2 + 880.45x - \text{RFU}_i = 0$$

- c. Determine amount of NAD remaining at each inhibitor concentration by solving for the value of X that falls on the standard curve.

The solution of the quadratic equation is

$$x = \frac{-b \pm \sqrt{b^2 - 4ac}}{2a}$$


Where $a = -4.4601$, $b = 880.45$ and $c = -\text{RFU}_i$ observed at each inhibitor concentration.

Figure 4: Calculate amount of NAD remaining (Excel).

	A	B	C	D	E	F	G	H
1	a	b	c	X1	X2			
2	-4.4601	880.54	-43053	89.1558	108.2702			
3								
4		[EB47] = 100 nM, RFU=43053						
5								
6		X1 (+)	=89.156	=(-B2 + SQRT(B2^2 - 4*A2*C2))/(2*A2)				
7		X2 (-)	=108.27	=(-B2 - SQRT(B2^2 - 4*A2*C2))/(2*A2)				

4. Plot the NAD remaining (% inhibition) on the Y axis versus inhibitor concentration on X axis using EXCEL. A log scale is used for the X axis.
5. The IC_{50} is estimated from the curve at 50% inhibition. For example, the inhibitor EB47 results in an estimated value of 25 nM at 50% inhibition (Figure 5).

Figure 5: Inhibition of PARP by EB47.



6. Equivalent RFU values should be obtained from the 100 nM Standard and Cycling Control to assure no inhibition of the cycling reaction.

Table 6: Relative IC_{50} values for known PARP inhibitors *

PARP Inhibitors	Observed K_i *	Published K_i
3-aminobenzamide	$51 \pm 10 \mu\text{M}$	$33 \mu\text{M}$
4-amino-1,8-naphthalimide	$23 \pm 7 \text{ nM}$	$153\text{-}180 \text{ nM}$
6(5H)-phenanthridinone	$408 \pm 130 \text{ nM}$	305 nM
Benzamide	$21 \pm 5 \mu\text{M}$	$1\text{-}22 \mu\text{M}$
PJ34	$139 \pm 55 \text{ nM}$	20 nM
EB47	$25 \pm 6 \text{ nM}$	45 nM

*Average of multiple experiments

VIII. References

1. Meyer-Ficca, M.L., et al., *Poly(ADP-ribose) polymerases: managing genome stability*. Int J Biochem Cell Biol, 2005. **37**(5): p. 920-6.
2. Hassa, P.O., et al., *Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going?* Microbiol Mol Biol Rev, 2006. **70**(3): p. 789-829.
3. Virag, L. and C. Szabo, *The therapeutic potential of poly(ADP-ribose) polymerase inhibitors*. Pharmacol Rev, 2002. **54**(3): p. 375-429.
4. Tutt, A.N., et al., *Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer*. Cold Spring Harb Symp Quant Biol, 2005. **70**: p. 139-48.
5. Bryant, H.E., et al., *Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase*. Nature, 2005. **434**(7035): p. 913-7.
6. Ratnam, K. and J.A. Low, *Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology*. Clin Cancer Res, 2007. **13**(5): p. 1383-8.

IX. Troubleshooting

PROBLEM	CAUSE	SOLUTION
No fluorescence in wells with NAD Standards	Low activity of Cycling Enzymes	Mix 10X Cycling Enzymes gently before adding to Cycling Mix.
High fluorescence in all wells	Resazurin is reduced. 10X Resazurin light sensitive. Plates	Do not add reducing agents (ex. DTT). Prepare Cycling Mix just before use. Read fluorescence at completion of Cycling reaction. Minimize exposure to light. Purchase plates suitable for fluorescent assays
NAD Standard Curve is flat at higher concentrations.	Low [EtOH]	Use 190 proof EtOH (95%)
Poor sensitivity and dynamic range of NAD Standards	Fluorescent plate reader settings.	Perform gain adjustment for entire plate to optimize the signal amplification
High fluorescence with PARP Control	Low PARP activity	Lower DMSO levels if present Store PARP at -20°C. Mix gently before adding to PARP reaction
PARP inhibition expected but not observed.	Inhibition of Cycling Reaction.	Titrate inhibitor and perform inhibitor only controls with Cycling reaction.

X. Related Products Available From Trevigen

Kits:

Catalog #	Description	Size
4671-096-K	HT Universal Color PARP Assay Kit/w Histone Reagents	96 tests
4675-096-K	HT Universal Chemiluminescent PARP Assay Kit/w Histone Reagent	96 tests
4676-096-K	HT Universal Chemiluminescent PARP Assay Kit/w Histone Coated Strip Wells	96 tests
4677-096-K	HT Universal Colorimetric PARP Assay Kit/w Histone Coated Strip Wells	96 tests
4684-096-K	HT Colorimetric PARP/Apoptosis Assay	96 tests
4685-096-K	HT Chemiluminescent PARP/Apoptosis Assay	96 tests
4682-096-K	HT Chemiluminescent PARG Assay Kit	96 tests
4683-096-K	HT Colorimetric PARG Assay Kit	96 tests

Inhibitors and Antibodies:

Catalog #	Description	Size
4667-50-11	Benzamide PARP inhibitor (8 mM)	100 µl
4667-50-03	3-Aminobenzamide PARP inhibitor (200 mM)	100 µl
4667-50-10	6(5H)-Phenanthridinone PARP inhibitor (160 µM)	100 µl
4667-50-9	4-Amino-1,8-naphthalimide PARP inhibitor (800 µM)	100 µl
4335-AMC-50	PAR Monoclonal Antibody Affinity Purified	50 µl
4335-MC-100	Anti-PAR Monoclonal Antibody	100 µl
4336-APC-50	PAR Polyclonal Antibody Affinity Purified	50 µl
4336-BPC-100	Anti-PAR Polyclonal Antibody (rabbit)	100 µl
4338-MC-50	Anti-PARP Monoclonal Antibody (clone C2-10)	50 µg
2305-PC-100	Anti-Cleaved Caspase 3 Polyclonal	100 µl

Poly(ADP)-ribose:

Catalog #	Description	Size
4336-100-01	Poly(ADP) Ribose (PAR) Polymer	100 µl

The product accompanying this document is intended for research use only and is not intended for diagnostic purposes or for use in humans.

Trevigen, Inc.

8405 Helgerman Ct. Gaithersburg, MD 20877

Tel: 1-800-873-8443 • 301-216-2800

Fax: 301-560-4973

e-mail: info@trevigen.com

www.trevigen.com



Please
Recycle